TW200626168A - Ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment - Google Patents

Ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment

Info

Publication number
TW200626168A
TW200626168A TW094101491A TW94101491A TW200626168A TW 200626168 A TW200626168 A TW 200626168A TW 094101491 A TW094101491 A TW 094101491A TW 94101491 A TW94101491 A TW 94101491A TW 200626168 A TW200626168 A TW 200626168A
Authority
TW
Taiwan
Prior art keywords
hepatitis
lamivudine
preparation
comphoratum
ganoderma
Prior art date
Application number
TW094101491A
Other languages
Chinese (zh)
Inventor
Wan-Sheng Ke
Hui-Yu Huang
xiao-ling Lu
Chang-Cheng Qiao
Jing-Chu Chen
Qing-Nong Chen
sheng-jie Xu
Original Assignee
Wan-Sheng Ke
Hui-Yu Huang
Chang-Cheng Qiao
Grape King Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wan-Sheng Ke, Hui-Yu Huang, Chang-Cheng Qiao, Grape King Inc filed Critical Wan-Sheng Ke
Priority to TW094101491A priority Critical patent/TW200626168A/en
Publication of TW200626168A publication Critical patent/TW200626168A/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment applies ganoderma comphoratum seed or ganoderma comphoratum mycelium; in which the aforementioned materials are ground into powder after drying from freezing, or optionally mixed with excipient, thinner, or carrier solvent into various types of dosage. When the dosage mixed with lamivudine is provided to hepatitis B patients, the ganoderma comphoratum preparation helps to produce antibody to neutralize virus by enhancing the immunoreaction of B cell and poisoning T cell, killing infected liver cell to increase the ratio of negative e-antigen among hepatitis B patients, and reducing the amount of DNA virus contained in hepatitis B virus for an effective treatment of hepatitis B with lamivudine.
TW094101491A 2005-01-19 2005-01-19 Ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment TW200626168A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW094101491A TW200626168A (en) 2005-01-19 2005-01-19 Ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW094101491A TW200626168A (en) 2005-01-19 2005-01-19 Ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment

Publications (1)

Publication Number Publication Date
TW200626168A true TW200626168A (en) 2006-08-01

Family

ID=57808766

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094101491A TW200626168A (en) 2005-01-19 2005-01-19 Ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment

Country Status (1)

Country Link
TW (1) TW200626168A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755356A (en) * 2011-04-28 2012-10-31 丽丰实业股份有限公司 Antiviral drug composition
CN113795258A (en) * 2019-02-25 2021-12-14 吉亚生技控股股份有限公司 Methods and compositions for inhibiting viral infection

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755356A (en) * 2011-04-28 2012-10-31 丽丰实业股份有限公司 Antiviral drug composition
CN113795258A (en) * 2019-02-25 2021-12-14 吉亚生技控股股份有限公司 Methods and compositions for inhibiting viral infection
CN113795258B (en) * 2019-02-25 2024-04-16 吉亚生技控股股份有限公司 Methods and compositions for inhibiting viral infection

Similar Documents

Publication Publication Date Title
WO2007008657A3 (en) Hepatitis c virus inhibitors
MY166979A (en) Dry storage stabilizing compositions for biological materials
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2007067959A3 (en) Ctla-4 antibody dosage escalation regimens
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2009041643A1 (en) Method of modifying isoelectric point of antibody via amino acid substitution in cdr
JP2017524002A5 (en)
WO2008021927A3 (en) Hepatitis c virus inhibitors
EA201490903A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF VIRAL HEPATITIS C
EA200801050A1 (en) COMPOUNDS AND METHODS OF INHIBITING THE REPLICATION OF VIRAL HEPATITIS C
MX2009006786A (en) Compositions and methods for the treatment of infections and tumors.
NO20090453L (en) Hepatitis C Virus Inhibitors
NZ609564A (en) Inhibitors of hepatitis c virus
WO2012006500A3 (en) Monoclonal antibodies against hepatitis c virus core protein
GB201013215D0 (en) Expression of antibody or a fragment thereof in lactobacillus
TW200626168A (en) Ganoderma comphoratum Zang et Su preparation with lamivudine for hepatitis B treatment
WO2003082330A1 (en) Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
JP2008503468A5 (en)
WO2007018556A3 (en) Method for detection and decontamination of antigens by nanoparticle-raman spectroscopy
RU2008151516A (en) METHOD FOR INCREASING THE BIOLOGICAL ACTIVITY OF PURIFIED HSPE7 PROTEIN
EP1541135A4 (en) Hollow nanoparticle having modified cysteine residue and drug with the use thereof
EP2336173A4 (en) Antibody capable of binding to envelope protein 2 of hepatitis c virus, and method for identifying genotype of hepatitis c virus using same
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
CN102755356B (en) Antiviral drug composition
WO2003082345A1 (en) Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith